[Translation] A single-center, randomized, double-blind, controlled clinical trial to evaluate the immunogenicity and safety of the scaled-up recombinant human papillomavirus 6/11/16/18/31/33/45/52/58 9-valent vaccine (Escherichia coli) in Chinese women aged 18-26 years

主要目的：评价重组人乳头瘤病毒6/11/16/18/31/33/45/52/58型九价疫苗（大肠埃希菌，600L工艺）的免疫原性是否非劣效于重组人乳头瘤病毒6/11/16/18/31/33/45/52/58型九价疫苗（大肠埃希菌，60L工艺）。次要目的：评价试验疫苗的安全性。

[Translation]

Primary objective: To evaluate whether the immunogenicity of the recombinant human papillomavirus 6/11/16/18/31/33/45/52/58 nine-valent vaccine (Escherichia coli, 600L process) is non-inferior to that of the recombinant human papillomavirus 6/11/16/18/31/33/45/52/58 nine-valent vaccine (Escherichia coli, 60L process). Secondary objective: To evaluate the safety of the experimental vaccine.

Start Date06 Apr 2024

Sponsor / Collaborator

Xiamen Innovax Biotech Co., Ltd.

[+2]

NCT06306196 / Not yet recruitingPhase 2IIT

A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin® in Children

The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses (0, 1 and 6 months) and to assess and descriptively compare safety profile data intra and inter age Strata. As secondary objectives, Geometric Mean Concentration (GMC) of anti-HEV IgG ELISA will be evaluated 4 weeks after 3 doses (0, 1 and 6 months) and 4 weeks after 2 doses (0- and 6-months dose) in healthy children. SR and GMC will also be evaluated 24 weeks after 3 doses and 2 doses. The immune response will be compared among adult participants between HIV positive and HIV negative individuals and between virally suppressed and virally unsuppressed HIV positive individuals

Start Date01 Apr 2024

Sponsor / Collaborator

International Vaccine Institute

[+2]

NCT06243666 / Not yet recruitingNot ApplicableIIT

Long-term Effectiveness and Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Girls Aged 9-17 Years

The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.

Start Date20 Feb 2024

Sponsor / Collaborator

Xiamen University

[+1]

100 Clinical Results associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

0 Patents (Medical) associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Literatures (Medical) associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

01 Aug 2024·The Lancet Infectious Diseases

Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial

Article

Author: Huang, Yue ; Wang, Wei ; Cheng, Tong ; Xu, Jin-Bo ; Qiu, Ling-Xian ; Huang, Shou-Jie ; Jia, Ji-Zong ; Su, Ying-Ying ; Zhang, Jun ; Han, Jin-Le ; Zhang, Ming-Lei ; Zhong, Guo-Hua ; Zhu, Hua ; Ye, Xiang-Zhong ; Li, Chang-Gui ; Li, Jia-Xue ; Fan, Yong ; Liang, Qi ; Liao, Meng-Jun ; Pan, Hong-Xing ; Chen, Zhen ; Wu, Ting ; Xia, Ning-Shao ; Zhu, Feng-Cai ; Liu, Sheng ; Hu, Jia-Lei ; Zhu, Kong-Xin

BACKGROUNDThe Oka varicella vaccine strain remains neurovirulent and can establish lifelong latent infection, raising safety concerns about vaccine-related herpes zoster. In this study, we aimed to evaluate the immunogenicity and safety of a skin-attenuated and neuro-attenuated varicella vaccine candidate (v7D vaccine).METHODSWe did this randomised, double-blind, controlled, phase 2a clinical trial in Jiangsu, China. Healthy children aged 3-12 years with no history of varicella infection or vaccination were enrolled and randomly assigned (1:1:1:1) to receive a single subcutaneous injection of the v7D vaccine at 3·3 log₁₀ plaque forming units (PFU; low-dose v7D group), 3·9 log₁₀ PFU (medium-dose v7D group), and 4·2 log₁₀ PFU (high-dose v7D group), or the positive control varicella vaccine (vOka vaccine group). All the participants, laboratory personnel, and investigators other than the vaccine preparation and management staff were masked to the vaccine allocation. The primary outcome was assessment of the geometric mean titres (GMTs) and seroconversion rates of anti-varicella zoster virus immunoglobulin G (IgG) induced by different dose groups of v7D vaccine at 0, 42, 60, and 90 days after vaccination in the per-protocol set for humoral immune response analysis. Safety was a secondary outcome, focusing on adverse events within 42 days post-vaccination, and serious adverse events within 6 months after vaccination. This study was registered on Chinese Clinical Trial Registry, ChiCTR2000034434.FINDINGSOn Aug 18-21, 2020, 842 eligible volunteers were enrolled and randomly assigned treatment. After three participants withdrew, 839 received a low dose (n=211), middle dose (n=210), or high dose (n=210) of v7D vaccine, or the vOka vaccine (n=208). In the per-protocol set for humoral immune response analysis, the anti-varicella zoster virus IgG antibody response was highest at day 90. At day 90, the seroconversion rates of the low-dose, medium-dose, and high-dose groups of v7D vaccine and the positive control vOka vaccine group were 100·0% (95% CI 95·8-100·0; 87 of 87 participants), 98·9% (93·8-100·0; 87 of 88 participants), 97·8% (92·4-99·7; 91 of 93 participants), and 96·4% (89·8-99·2; 80 of 83 participants), respectively; the GMTs corresponded to values of 30·8 (95% CI 26·2-36·0), 31·3 (26·7-36·6), 28·2 (23·9-33·2), and 38·5 (31·7-46·7). The v7D vaccine, at low dose and medium dose, elicited a humoral immune response similar to that of the vOka vaccine. However, the high-dose v7D vaccine induced a marginally lower GMT compared with the vOka vaccine at day 90 (p=0·027). In the per-protocol set, the three dose groups of the v7D vaccine induced a similar humoral immune response at each timepoint, with no statistically significant differences. The incidence of adverse reactions in the low-dose, medium-dose, and high-dose groups of v7D vaccine was significantly lower than that in the vOka vaccine group (17% [35 of 211 participants], 20% [41 of 210 participants], and 13% [27 of 210 participants] vs 24% [50 of 208 participants], respectively; p=0·025), especially local adverse reactions (10% [22 of 211 participants], 14% [30 of 210 participants] and 9% [18 of 210 participants] vs 18% [38 of 208 participants], respectively; p=0·016). None of the serious adverse events were vaccine related.INTERPRETATIONThe three dose groups of the candidate v7D vaccine exhibit similar humoral immunogenicity to the vOka vaccine and are well tolerated. These findings encourage further investigations on two-dose vaccination schedules, efficacy, and the potential safety benefit of v7D vaccine in the future.FUNDINGThe National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, the Fundamental Research Funds for the Central Universities, and Beijing Wantai.TRANSLATIONFor the Chinese translation of the abstract see Supplementary Materials section.

01 May 2024·Vaccine

Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys

Article

Author: Zeng, Yuanjun ; Xia, Ningshao ; Ge, Shengxiang ; Zhang, Shiyin ; Yang, Han ; Li, Tingdong ; Zhang, Zhishan ; Chen, Yaling ; Zhang, Jun ; Sheng, Roufang ; Luo, Guoxing ; Song, Feibo ; Li, Cao

Group A rotavirus (RVA) is the primary etiological agent of acute gastroenteritis (AGE) in children under 5 years of age. Despite the global implementation of vaccines, rotavirus infections continue to cause over 120,000 deaths annually, with a majority occurring in developing nations. Among infants, the P[8] rotavirus strain is the most prevalent and can be categorized into four distinct lineages. In this investigation, we expressed five VP4(aa26-476) proteins from different P[8] lineages of human rotavirus in E. coli and assessed their immunogenicity in rabbits. Among the different P[8] strains, the Wa-VP4 protein, derived from the MT025868.1 strain of the P[8]-1 lineage, exhibited successful purification in a highly homogeneous form and significantly elicited higher levels of neutralizing antibodies (nAbs) against both homologous and heterologous rotaviruses compared to other VP4 proteins derived from different P[8] lineages in rabbits. Furthermore, we assessed the immunogenicity of the Wa-VP4 protein in mice, pigs, and cynomolgus monkeys, observing that it induced robust production of nAbs in all animals. Interestingly, there was no significant difference between in nAb titers against homologous and heterologous rotaviruses in pigs and mankeys. Collectively, these findings suggest that the Wa-VP4* protein may serve as a potential candidate for a rotavirus vaccine.

30 Apr 2024·PNAS Nexus

Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters

Article

Author: Chen, Yaode ; Wei, Dongmei ; Chen, Congjie ; Chen, Yixin ; Ye, Xiangzhong ; Yuan, Lunzhi ; Chen, Junyu ; Xia, Ningshao ; Wang, Xijing ; Tang, Ningxin

AbstractThe XBB.1.5 subvariant has garnered significant attention due to its exceptional immune evasion and transmissibility. Significantly, the evolutionary trajectory of SARS-CoV-2 has shown continual progression, with a recent global shift observed from XBB to BA.2.86, exemplified by the emergence of the predominant JN.1 subvariant. This phenomenon highlights the need for vaccines that can provide broad-spectrum antigenic coverage. In this study, we utilized a NS1-deleted (dNS1) influenza viral vector to engineer an updated live-attenuated vectored vaccine called dNS1-XBB-RBD. This vaccine encodes the receptor-binding domain (RBD) protein of the XBB.1.5 strain. Our findings demonstrate that the dNS1-XBB-RBD vaccine elicits a similar systemic and mucosal immune response compared to its prototypic form, dNS1-RBD. In hamsters, the dNS1-XBB-RBD vaccine provided robust protection against the SARS-CoV-2 immune-evasive strains XBB.1.9.2.1 and Beta. Remarkably, nasal vaccination with dNS1-RBD, which encodes the ancestor RBD gene, also effectively protected hamsters against both the XBB.1.9.2.1 and Beta strains. These results provide valuable insights about nasal influenza-vectored vaccine and present a promising strategy for the development of a broad-spectrum vaccine against COVID-19 in the future.

News (Medical) associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

16 Mar 2024

·www.prnewswire.com

Global HIV Point of Care (POC) Tests Pipeline Landscape Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

DUBLIN, March 15, 2024 /PRNewswire/ -- The "HIV Point of Care (POC) Tests Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information about the HIV Point of care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. HIV Point of care (POC) Tests is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often 'handheld' or may be small portable analyzers. Scope Extensive coverage of the HIV Point of care (POC) Tests under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of HIV Point of care (POC) Tests and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of HIV Point of care (POC) Tests under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 HIV Point of care (POC) Tests Overview 3 Products under Development 3.1 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development 3.2 HIV Point of care (POC) Tests - Pipeline Products by Territory 3.3 HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path 3.4 HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date 3.5 HIV Point of care (POC) Tests - Ongoing Clinical Trials 4 HIV Point of care (POC) Tests - Pipeline Products under Development by Companies 4.1 HIV Point of care (POC) Tests Companies - Pipeline Products by Stage of Development 4.2 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development 5 HIV Point of care (POC) Tests Companies and Product Overview 6 HIV Point of care (POC) Tests- Recent Developments 6.1 Oct 10, 2023: Trinity Biotech Welcomes the Decision of the High Court of Kenya to Strike Out the Applications to Prevent the Procurement of Trinscreen HIV by the Kenyan Ministry of Health 6.2 Sep 27, 2023: Update on MedMira's Regulatory Path in Canada and the USA 6.3 Jun 14, 2023: Atomo and Newfoundland Sign Agreement for HIV Testing in Europe 6.4 Mar 22, 2023: Trinity Biotech welcomes TrinScreen HIV's inclusion in the New Kenyan HIV Testing Algorithm 6.5 Feb 28, 2023: Significant purchase order for HIV self-tests for Europe 7 Appendix A selection of companies mentioned in this report includes Abbott Rapid Diagnostics GmbH Aldatu Biosciences Inc Altratech Ltd Atomo Diagnostics Ltd Baebies Inc BBB Technologies Inc Beijing Wantai Biological Pharmacy Enterprise Co Ltd Binx Health Inc Bio-AMD Inc Biocartis Group NV BioHelix Corp Bluejay Diagnostics Inc Calypte Biomedical Corporation Centre International de Reference Chantal Biya Cepheid Inc ChipCare Corp CrossLife Technologies Inc Cue Inc Daktari Diagnostics, Inc. Diagnostics For All Inc Diagnostics for the Real World (Europe) Ltd Endeavor Sciences Inc Epinex Diagnostics Inc ERBA Molecular Ltd Fluxergy LLC GAIA Medical Institute LLC genedrive plc Group K Diagnostics Guangzhou Wondfo Biotech Co Ltd HA TECH Pty Ltd HeatFlow Technologies Inc Identifysensors LLC Imperial College London Integrated Diagnostics Inc (Inactive) Intuitive Biosciences Inc Jan Biotech Inc Jinvator Bio Med GmbH Johns Hopkins University Lynntech Inc Maxim Biomedical Inc MedMira Inc Micronics Inc Molbio Diagnostics Pvt Ltd MyMD Pharmaceuticals Inc Nanobiosym Inc Newmark Diagnostics LLC Northwestern University Osel Inc Philmedi Co Ltd Prenetics Ltd QuantuMDx Group Ltd Quidel Corp Radisens Diagnostics Ltd Rheonix Inc Roche Diagnostics International Ltd Sedia Biosciences Corp Sensible Diagnostics Inc Senzo Inc TheoremDx Inc Trinity Biotech Plc University of Connecticut University of Minnesota UrSure Inc Ustar Biotechnologies (Hangzhou) Ltd. Virax Biolabs Group Ltd Wave 80 Biosciences Inc Yaathum Biotech Pvt Ltd For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

01 Mar 2024

·www.prnewswire.com

Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cervical Cancer - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial report provides an overview of Cervical Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Cervical Cancer and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Report Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Key Benefits Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Cervical Cancer to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Cervical Cancer to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Cervical Cancer Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Company Coverage: Merck & Co Inc GSK plc F. Hoffmann-La Roche Ltd AstraZeneca Plc Pfizer Inc Bristol-Myers Squibb Co Jiangsu Hengrui Medicine Co Ltd Xiamen Innovax Biotech Co Ltd Sanofi Yangshengtang Co Ltd For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Clinical StudyASCO

17 Jan 2023

·www.prnewswire.com

The Evolution of Fourth - Fifth Generation HIV Rapid Test Kits is Booming, the Market to Create USD 2 Billion Opportunities by 2028 - Arizton

The application of fourth-generation and fifth-generation rapid test kits is currently high. The adoption and innovation of digital HIV self-testing tools have increased in recent times, with website-based innovation becoming highly popular. CHICAGO, Jan. 17, 2023 /PRNewswire/ -- According to Arizton's latest research report, the global HIV rapid test kits market will grow at a CAGR of 2.7% from 2022-2028. HIV rapid test kits have evolved into advanced forms of testing. The application of fourth-generation and fifth-generation rapid test kits is currently high in the market and is expected to become popular in the upcoming years. Fourth-generation HIV test kits are designed to identify HIV antibodies with a blood sample and HIV-specific antigen (p24). Hence, the introduction of fourth-generation HIV kits expects to increase the revenue of the blood sample-based kits in the upcoming years as their acceptance is likely to increase. Older-generation HIV test kits, such as third-generation HIV test kits, are unreliable until three months after exposure to HIV. Hence, these limitations increase the demand for fourth-generation HIV rapid test kits globally. Continue Reading HIV Rapid Test Kits Market Moreover, the introduction of digital support for HIV self-testing and government initiatives to boost the sales of the market. The application of digital tools in HIV management is increasing rapidly, which is expected to fuel the adoption of HIV self-testing rapid test kits. These interventions are currently improving HIV care and diagnosis. In 2021–2022, the HIV Self-Testing (HIVST) deployment and digital tool integrations in health services were emerging, but it was a priority for UNAIDS. In healthcare services, digital health technologies are achieving high traction in high-and middle-income countries. Furthermore, telemedicine has allowed the continuity of HIV care for many patients. The COVID-19 pandemic covers the roadmap for the evolution of HIV self-testing with digital support to reduce the gap in HIV care deliveries. . The application of digital tools in HIV management is increasing rapidly, which is expected to fuel the adoption of HIV self-testing rapid test kits. These interventions are currently improving HIV care and diagnosis. In 2021–2022, the HIV Self-Testing (HIVST) deployment and digital tool integrations in health services were at an emerging stage, but it was a priority for UNAIDS. In healthcare services, digital health technologies are achieving high traction in high-and middle-income countries. Furthermore, telemedicine has allowed the continuity of HIV care for many patients. The COVID-19 pandemic covers the roadmap for the evolution of HIV self-testing with digital support to reduce the gap in HIV care deliveries. Implementing digital tools in the HIV rapid test kits market has a high potential to reach diverse audiences with the potential for widespread scale-up. The effective and efficient linkage between health services and patients increasing access to HIV testing. These factors are expected to increase HIV rapid test adoption in the diverse patient population, thereby driving the demand for market growth in upcoming years. According to the Lancet, the adoption and innovation of digital HIV self-testing tools have increased in recent times, with website-based innovation becoming highly popular. Around 54% of HIV self-testing digital tool innovations are related to website-based innovations based on studies run by the Lancet. These studies are conducted in Asia, North America, Europe, South America, and Africa. Digital tools support in HIVST have been acceptable, feasible, and preferable in the last decades, however, they are currently showing uptake, with improvement in the access to HIV rapid test kits and associated clinical outcomes. Global HIV Rapid Test Kits Market Report Scope Click Here to Download the Free Sample Report North America, APAC, Middle East & Africa, Europe, and Latin America are the major geographies covered in the global HIV rapid test kits market. In 2022, North America accounted for a 31.06% share of the global HIV rapid test kits market and dominated it with high revenue generation. The factors propelling the market growth in the region are high HIV prevalence and increasing awareness of the disease. In addition, government-backed programs and initiatives for HIV self-testing support the market growth in the region. APAC and Middle East Africa regions expect to offer lucrative market growth opportunities during the forecast period. According to the Lancet, the adoption and innovation of digital HIV self-testing tools have increased in recent times, with website-based innovation becoming highly popular. Around 54% of HIV self-testing digital tool innovations are related to website-based innovations based on studies run by the Lancet. These studies are conducted in Asia, North America, Europe, South America, and Africa. Digital tools support in HIVST have been acceptable, feasible, and preferable in the last decades, however, they are currently showing uptake, with improvement in the access to HIV rapid test kits and associated clinical outcomes. Some companies collaborating with the WHO and UNAIDS to increase the rate of HIV self-testing, thereby supporting HIV rapid test kits market growth. In 2022, the WHO partnered with the Clinton Health Access Initiative (CHAI), Wondfo Biotech Company, and MedAccess. These partnerships make available HIV-self-test kits for only $1 in the public sector in LMICs. This is expected to increase the high market competition among leading market players. Inorganic growth strategies by leading market players have creating entry barriers for many small and emerging players. ADOPTION OF INNOVATION LATERAL FLOW IMMUNOASSAY IS HIGH ACROSS HIV RAPID TEST KITS MARKET Several companies in the market are coming up with low-cost lateral flow-based HIV test kits. Many regulatory bodies, such as the WHO and other NGOs, are funding HIV test kit manufacturing. This will help companies to come up with unique products in the market. The level of innovations in the lateral flow immune assay is high in the market. In LMICs, there is a constant rise in the prevalence of HIV infection, which demands the usage of HIV rapid diagnostic test kits to increase significantly. Lateral flow immune assays are more user-friendly and are highly used among people with limited access to healthcare settings. Most health authorities and healthcare settings suggest immunochromatographic rapid test kits. In western African countries, the newly developed and available HIV rapid test kits, which are developed based on the immunochromatographic assay, are commonly used. Market players expect to have high market growth opportunities in Africa. Click Here to Download the Free Sample Report KEY COMPANY PROFILES Abbott Bio-Rad Laboratories BIOMÉRIEUX Chembio Diagnostics OraSure Technologies Atomo Diagnostics AccuBioTech bioLytical Laboratories Biosynex Cupid Limited DIALAB HUMAN INTEC J. Mitra & Co Meril Life Sciences MP Biomedicals Medsource Ozone Biomedicals Nanjing Synthgene Medical Technology Premier Medical SD Biosensor KHB (Shanghai Kehua Bio-Engineering co., Ltd.) Türklab A.S. Trinity Biotech Wantai BioPharma Wondfo MARKET SEGMENTATION Technology Lateral Flow Immunoassay Immunofiltration Sample Type Blood Oral Fluid Urine Distribution Channels Offline Online Geography North America US Canada Europe France Italy Ukraine Portugal Russia APAC China India Indonesia Thailand Vietnam Latin America Brazil Mexico Columbia Middle East & Africa South Africa Mozambique Kenya Nigeria Tanzania CHECK OUT SOME OF THE TOP-SELLING RESEARCH RELATED REPORTS Fertility Test Market - Global Outlook & Forecast 2022-2027: The global fertility test market is expected to reach USD 659.71 million by 2027. The global fertility treatment is presumably to grow at a healthy rate due to attractive long-term growth from favorable demographic and social/cultural shifts. Fertility testing is a niche industry with high margins for manufacturers, especially for vendors offering kits, which males and females widely use. Lateral Flow Assays Market - Global Outlook & Forecast 2023-2028: The global lateral flow assays market is expected to reach USD 11.30 billion by 2028. The market is one of the major segments in the global point of care or the rapid diagnostics market and is growing steadily and is anticipated to grow at a similar pace during the forecast period. Further, the growth in the market is attributed to the increasing prevalence/incidence of various infectious and chronic diseases. In addition, malaria is still a cause of death in a few regions. For instance, according to the WHO, malaria is one of the leading causes of death in the Middle East & Africa. COVID-19 Rapid Antigen Test Kits Market - Global Outlook & Forecast 2022-2027: The COVID-19 rapid antigen tests market is expected to reach $743.07 million by 2027. Antigen tests are commonly used in the diagnosis of pathogens, including influenza viruses and respiratory syncytial viruses. These tests are immunoassays that detect specific viral antigen and confirms the presence or absence of viral infection. Rapid antigen tests are currently authorized to be performed on nasal or nasopharyngeal swab specimens placed directly into the immunoassay's extraction buffer or reagent. The currently available rapid antigen tests include point-of-care (POC) and laboratory-based tests, as well as self-tests performed at home, and they are commercially available to people of any age. DNA Extraction Kit Market – Global Outlook & Forecast 2022-2027: The DNA extraction kit market size is expected to reach USD 2.1 billion by 2027. North America dominated the DNA extraction kit market share. However, APAC is expected to grow at a faster rate, with a CAGR of over 9% in the DNA extraction market. The increasing investments in genome sequencing, increasing adoption of genetic testing-based diagnostics for rare diseases, oncology, and higher adoption of personalized medicines are largely driving the North America Market. WHY ARIZTON? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 5+ years of experience in delivering Insights at the Global, Regional & Country Level TABLE OF CONTENT 1 RESEARCH METHODOLOGY 2 RESEARCH OBJECTIVES 3 RESEARCH PROCESS 4 SCOPE & COVERAGE 4.1 MARKET DEFINITION 4.1.1 INCLUSIONS 4.1.2 EXCLUSIONS 4.1.3 MARKET ESTIMATION CAVEATS 4.2 BASE YEAR 4.3 SCOPE OF THE STUDY 4.3.1 MARKET BY TECHNOLOGY 4.3.2 MARKET BY SAMPLE TYPE 4.3.3 MARKET BY DISTRIBUTION CHANNELS 4.3.4 MARKET SEGMENTATION BY GEOGRAPHY 5 REPORT ASSUMPTIONS & CAVEATS 5.1 KEY CAVEATS 5.2 CURRENCY CONVERSION 5.3 MARKET DERIVATION 6 MARKET AT A GLANCE 7 PREMIUM INSIGHTS 7.1 OVERVIEW 8 INTRODUCTION 8.1 OVERVIEW 9 MARKET OPPORTUNITIES & TRENDS 9.1 INTRODUCTION OF NEXT GENERATION HIV RAPID TEST KITS 9.2 INCREASE IN HIV SELF-TESTING BY GOVERNMENT BODIES 9.3 DIGITAL SUPPORT FOR HIV SELF-TESTING 10 MARKET GROWTH ENABLERS 10.1 INCREASING HIV PATIENT POPULATION 10.2 INCREASED RESOURCES AVAILABILITY AND FUNDING FOR HIV MANAGEMENT 10.3 INCREASED AWARENESS OF HIV SELF-TESTING 11 MARKET RESTRAINTS 11.1 INCREASING INCIDENCES OF FALSE NEGATIVES 11.2 LIMITATIONS & CHALLENGES ASSOCIATED WITH HIV TESTING 11.3 LOW ACCESSIBLITY & LACK OF AWARENESS FOR HIVST 12 MARKET LANDSCAPE 12.1 MARKET OVERVIEW 12.1.1 INSIGHTS BY TECHNOLOGY 12.1.2 INSIGHTS BY SAMPLE TYPE 12.1.3 INSIGHTS BY DISTRIBUTION CHANNELS 12.1.4 INSIGHTS BY GEOGRAPHY 12.2 MARKET SIZE & FORECAST 12.3 FIVE FORCES ANALYSIS 12.3.1 THREAT OF NEW ENTRANTS 12.3.2 BARGAINING POWER OF SUPPLIERS 12.3.3 BARGAINING POWER OF BUYERS 12.3.4 THREAT OF SUBSTITUTES 12.3.5 COMPETITIVE RIVALRY 13 TECHNOLOGY 13.1 MARKET SNAPSHOT & GROWTH ENGINE 13.2 MARKET OVERVIEW 13.3 LATERAL FLOW IMMUNOASSAY 13.3.1 MARKET OVERVIEW 13.3.2 MARKET SIZE & FORECAST 13.3.3 MARKET BY GEOGRAPHY 13.4 IMMUNOFILTRATION 13.4.1 MARKET OVERVIEW 13.4.2 MARKET SIZE & FORECAST 13.4.3 MARKET BY GEOGRAPHY 14 SAMPLE TYPE 14.1 MARKET SNAPSHOT & GROWTH ENGINE 14.2 MARKET OVERVIEW 14.3 BLOOD 14.3.1 MARKET OVERVIEW 14.3.2 MARKET SIZE & FORECAST 14.3.3 MARKET BY GEOGRAPHY 14.4 ORAL FLUID 14.4.1 MARKET OVERVIEW 14.4.2 MARKET SIZE & FORECAST 14.4.3 MARKET BY GEOGRAPHY 14.5 URINE 14.5.1 MARKET OVERVIEW 14.5.2 MARKET SIZE & FORECAST 14.5.3 MARKET BY GEOGRAPHY 15 DISTRIBUTION CHANNEL 15.1 MARKET SNAPSHOT & GROWTH ENGINE 15.2 MARKET OVERVIEW 15.3 OFFLINE 15.3.1 MARKET OVERVIEW 15.3.2 MARKET SIZE & FORECAST 15.3.3 MARKET BY GEOGRAPHY 15.4 ONLINE 15.4.1 MARKET OVERVIEW 15.4.2 MARKET SIZE & FORECAST 15.4.3 MARKET BY GEOGRAPHY 16 GEOGRAPHY 16.1 MARKET SNAPSHOT & GROWTH ENGINE 16.2 GEOGRAPHIC OVERVIEW 17 NORTH AMERICA 17.1 MARKET OVERVIEW 17.2 MARKET SIZE & FORECAST 17.3 TECHNOLOGY 17.3.1 MARKET SIZE & FORECAST 17.4 SAMPLE TYPE 17.4.1 MARKET SIZE & FORECAST 17.5 DISTRIBUTION CHANNELS 17.5.1 MARKET SIZE & FORECAST 17.6 KEY COUNTRIES 17.6.1 US: MARKET SIZE & FORECAST 17.6.2 CANADA: MARKET SIZE & FORECAST 18 APAC 18.1 MARKET OVERVIEW 18.2 MARKET SIZE & FORECAST 18.3 TECHNOLOGY 18.3.1 MARKET SIZE & FORECAST 18.4 SAMPLE TYPE 18.4.1 MARKET SIZE & FORECAST 18.5 DISTRIBUTION CHANNELS 18.5.1 MARKET SIZE & FORECAST 18.6 KEY COUNTRIES 18.6.1 CHINA: MARKET SIZE & FORECAST 18.6.2 INDIA: MARKET SIZE & FORECAST 18.6.3 INDONESIA: MARKET SIZE & FORECAST 18.6.4 THAILAND: MARKET SIZE & FORECAST 18.6.5 VIETNAM: MARKET SIZE & FORECAST 19 MIDDLE EAST & AFRICA 19.1 MARKET OVERVIEW 19.2 MARKET SIZE & FORECAST 19.3 TECHNOLOGY 19.3.1 MARKET SIZE & FORECAST 19.4 SAMPLE TYPE 19.4.1 MARKET SIZE & FORECAST 19.5 DISTRIBUTION CHANNELS 19.5.1 MARKET SIZE & FORECAST 19.6 KEY COUNTRIES 19.6.1 SOUTH AFRICA: MARKET SIZE & FORECAST 19.6.2 MOZAMBIQUE: MARKET SIZE & FORECAST 19.6.3 KENYA: MARKET SIZE & FORECAST 19.6.4 NIGERIA: MARKET SIZE & FORECAST 19.6.5 TANZANIA: MARKET SIZE & FORECAST 20 EUROPE 20.1 MARKET OVERVIEW 20.2 MARKET SIZE & FORECAST 20.3 TECHNOLOGY 20.3.1 MARKET SIZE & FORECAST 20.4 SAMPLE TYPE 20.4.1 MARKET SIZE & FORECAST 20.5 DISTRIBUTION CHANNELS 20.5.1 MARKET SIZE & FORECAST 20.6 KEY COUNTRIES 20.6.1 FRANCE: MARKET SIZE & FORECAST 20.6.2 ITALY: MARKET SIZE & FORECAST 20.6.3 UKRAINE: MARKET SIZE & FORECAST 20.6.4 PORTUGAL: MARKET SIZE & FORECAST 20.6.5 RUSSIA: MARKET SIZE & FORECAST 21 LATIN AMERICA 21.1 MARKET OVERVIEW 21.2 MARKET SIZE & FORECAST 21.3 TECHNOLOGY 21.3.1 MARKET SIZE & FORECAST 21.4 SAMPLE TYPE 21.4.1 MARKET SIZE & FORECAST 21.5 DISTRIBUTION CHANNELS 21.5.1 MARKET SIZE & FORECAST 21.6 KEY COUNTRIES 21.6.1 BRAZIL: MARKET SIZE & FORECAST 21.6.2 MEXICO: MARKET SIZE & FORECAST 21.6.3 COLOMBIA: MARKET SIZE & FORECAST 22 COMPETITIVE LANDSCAPE 22.1 COMPETITION OVERVIEW 22.2 MARKET SHARE ANALYSIS 22.2.1 ABBOTT 22.2.2 BIO-RAD LABORATORIES 22.2.3 BIOMÉRIEUX 22.2.4 CHEMBIO DIAGNOSTICS 22.2.5 ORASURE TECHNOLOGIES 23 KEY COMPANY PROFILES 23.1 ABBOTT 23.1.1 BUSINESS OVERVIEW 23.1.2 PRODUCT OFFERINGS 23.1.3 KEY STRATEGIES 23.1.4 KEY STRENGTHS 23.1.5 KEY OPPORTUNITIES 23.2 BIO-RAD LABORATORIES 23.3 BIOMÉRIEUX 23.4 CHEMBIO DIAGNOSTICS 23.5 ORASURE TECHNOLOGIES 24 OTHER PROMINENT VENDORS 24.1 ATOMO DIAGNOSTICS 24.1.1 BUSINESS OVERVIEW 24.1.2 PRODUCT OFFERINGS 24.2 ACCUBIOTECH 24.3 BIOLYTICAL LABORATORIES 24.4 BIOSYNEX 24.5 CUPID LIMITED 24.6 HUMAN 24.7 INTEC 24.8 J. MITRA & CO 24.9 MERIL LIFE SCIENCES 24.10 MP BIOMEDICALS 24.11 MEDSOURCE OZONE BIOMEDICALS 24.12 NANJING SYNTHGENE MEDICAL TECHNOLOGY 24.13 PREMIER MEDICAL 24.14 SD BIOSENSOR 24.15 KHB (SHANGHAI KEHUA BIO-ENGINEERING) 24.16 TÜRKLAB A.S. 24.17 TRINITY BIOTECH 24.18 WANTAI BIOPHARMA 24.19 WONDFO 25 REPORT SUMMARY 25.1 KEY TAKEAWAYS 25.2 STRATEGIC RECOMMENDATIONS 26 QUANTITATIVE SUMMARY 26.1 MARKET BY GEOGRAPHY 26.2 MARKET BY TECHNOLOGY 26.3 MARKET BY SAMPLE TYPE 26.4 MARKET BY DISTRIBUTION CHANNELS 26.5 TECHNOLOGY: MARKET BY GEOGRAPHY 26.5.1 LATERAL FLOW IMMUNOASSAY: MARKET BY GEOGRAPHY 26.5.2 IMMUNOFILTRATION: MARKET BY GEOGRAPHY 26.6 SAMPLE TYPE: MARKET BY GEOGRAPHY 26.6.1 BLOOD SAMPLE TYPE: MARKET BY GEOGRAPHY 26.6.2 ORAL FLUID SAMPLE TYPE: MARKET BY GEOGRAPHY 26.6.3 URINE SAMPLE TYPE: MARKET BY GEOGRAPHY 26.7 DISTRIBUTION CHANNELS: MARKET BY GEOGRAPHY 26.7.1 OFFLINE DISTRIBUTION CHANNELS: MARKET BY GEOGRAPHY 26.7.2 ONLINE DISTRIBUTION CHANNELS: MARKET BY GEOGRAPHY 27 APPENDIX 27.1 ABBREVIATIONS About Us :   Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  Click Here to Contact Us  Call: +1-312-235-2040            +1 302 469 0707  Mail: [email protected] Photo: Logo: SOURCE Arizton Advisory & Intelligence

100 Deals associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

100 Translational Medicine associated with Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Human papillomavirus 16/18 vaccine recombinant bivalent(Xiamen Innovax)	Human Papillomavirus Infection More	Approved
DelNS1-2019-nCoV-RBD-OPT1(Beijing Wantai Biological) ( SARS-CoV-2 S protein )	COVID-19 More	Approved
Hepatitis E vaccine recombinant(Xiamen Innovax Biotech Co. Ltd.)	Hepatitis E More	Approved
9-Valent HPV Vaccine(Xiamen Innovax)	Human Papillomavirus Infection More	NDA/BLA
Human papillomavirus recombinant vaccine nonavalent (Xiamen Innovax Biotech)	Human Papillomavirus Infection More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis